BACE inhibitor BI 1181181 voluntarily put on temporary clinical hold for safety evaluation
Vitae Pharma announced its partner Boehringer Ingelheim has voluntarily placed BI 1181181 on a temporary clinical hold, and has notified regulatory agencies of its decision. BI 1181181 is an orally-active beta secretase inhibitor being evaluated in Phase 1 clinical trials for Alzheimer's disease. February 26, 2015